Sun Pharma Q3FY26 Net Profit Up By 16% At Rs 3,368.8 Crore

Sun Pharmaceutical Industries Ltd officially stated here on Saturday that it has posted a 16 per cent year-on-year (YoY) increase in its Q3FY26 net profit at Rs 3,368.8 crore as compared to its Rs 2,903 crore net profit in the same period last year.

The company’s board has declared an interim dividend of Rs 11 per equity share of Rs 1 each for FY26. The record date for the dividend is set for February 5, 2026, and the payout will be made on or before February 16, 2026.

Advertisement

Revenue from operations rose 13.5 per cent year-on-year to Rs 15,520.5 crore, surpassing Street estimates of Rs 14,874.7 crore. Sales for the quarter stood at Rs 15,469.1 crore, marking a 15.1 per cent increase from the year-ago period.

Sun Pharma’s operating performance also beat expectations. EBITDA is at Rs 4,984.4 crore, which is higher than estimates of Rs 4,285 crore and increased by 23.4 per cent from Rs 4,009 crore, a year ago. The company’s operating margin expanded to 31.9 per cent from 29.3 per cent last year and also exceeded analyst expectations of 28.8 per cent, as per the company statement.

The company reported exceptional items worth Rs 489.4 crore during the quarter, largely due to the implementation of new labour codes.

Sun Pharma stated that its global innovative medicines business posted sales of USD 423 million during the quarter, including a USD 55 million milestone payment. Excluding the milestone, innovative medicines sales grew at 13.2 per cent YoY and accounted for 21.2 per cent of its overall sales.

In the US, formulation sales remained resilient, marginally growing by 0.6per cent to USD 477 million. The company noted that the growth in its innovative medicines portfolio successfully offset the decline in its generics business there.

Commenting on the results, Sun Pharmaceutical Industries Managing Director Kirti Ganorkar said, “Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our Branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India”.

The company’s innovative R&D pipeline currently includes five novel entities in the clinical stage. In the US market, Sun Pharma has a broad product portfolio with US FDA-approved Abbreviated New Drug Applications (ANDAs) for 550 products, while 116 ANDA filings are pending approval from the US FDA, including 28 tentative approvals. During the quarter, the company filed two ANDAs and received approvals for two others.

The company’s India formulations business clocked sales of Rs 4,998.6 crore, registering a growth of 16.2 per cent , and its domestic market now accounts for approximately 32.3 per cent of the company’s total consolidated sales.